New aspect of anti-inflammatory action of lipo-prostaglandinE1 in the management of collagen diseases-related skin ulcer.
It is considered that the mechanism in intractable cutaneous ulcer is deeply associated with prolongation at the inflammatory phase. Having evaluated the effects of Lipo-prostaglandin E1 (Lipo-PGE1) with indicators such as the reduction ratio of the ulcer area and the values of the inflammatory markers after dividing them into two groups of collagen diseases and non-collagen diseases and giving them Lipo-PGE1, we managed to obtain the result that Lipo-PGE1 administration could influence various inflammatory markers such as C-reactive protein (CRP), IL-6, and VEGF in addition to reduction of the ulcer region. It also suggested that Lipo-PGE1 has the effect of maintaining an appropriate balance of induction of inflammation and angiogenesis. Additionally, it revealed that Lipo-PGE1 controls the production of cytokines, which are associated with the growth of collagen diseases. From these results, it can be expected that Lipo-PGE1 will act favorably on intractable collagen diseases.
Murota
Hiroyuki
H
Department of Dermatology Course of Integrated Medicine, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka Suita City, Osaka 565-0871, Japan. h-murota@derma.med.osaka-u.ac.jp
Kotobuki
Yorihisa
Y
Umegaki
Noriko
N
Tani
Mamori
M
Katayama
Ichiro
I
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000527:Alprostadil / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002097:C-Reactive Protein / Q000032:analysis; D015331:Cohort Studies; D003095:Collagen Diseases / Q000150:complications*; D005260:Female; D006801:Humans; D018799:Intercellular Adhesion Molecule-1 / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D008297:Male; D008875:Middle Aged; D012216:Rheumatic Diseases / Q000150:complications*; D012883:Skin Ulcer / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D042461:Vascular Endothelial Growth Factor A / Q000097:blood
D000893:Anti-Inflammatory Agents; C508600:IL6 protein, human; D015850:Interleukin-6; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D018799:Intercellular Adhesion Molecule-1; D002097:C-Reactive Protein; D000527:Alprostadil